<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ojrdrt</journal-id><journal-title-group><journal-title xml:lang="ru">Онкологический журнал: лучевая диагностика, лучевая терапия</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of oncology: diagnostic radiology and radiotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7593</issn><issn pub-type="epub">2713-167X</issn><publisher><publisher-name>НЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37174/2587-7593-2022-5-1-83-91</article-id><article-id custom-type="elpub" pub-id-type="custom">ojrdrt-223</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ СЛУЧАИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL CASES</subject></subj-group></article-categories><title-group><article-title>Успешная комбинированная системно-регионарная химиотерапия при распространенной внутрипеченочной холангиокарциноме: сообщение о двух наблюдениях</article-title><trans-title-group xml:lang="en"><trans-title>Successful Combined S Systemic-Regional Chemotherapy for Advanced Intrahepatic Cholangiocarcinoma: Report of Two Cases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9190-116X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Таразов</surname><given-names>П. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Tarazov</surname><given-names>P. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Таразов Павел Гадельгараевич — заведующий отделением ангиографии, главный научный сотрудник отдела интервенционной радиологии иоперативной хирургии, д.м.н., профессор, Заслуженный деятель науки РФ</p><p>SPIN-код 7089-7542</p><p>197758, Санкт-Петербург, п. Песочный, ул. Ленинградская, д. 70</p></bio><bio xml:lang="en"><p>197758, Saint Petersburg, p. Pesochny, Leningradskaya str., 70</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3323-7576</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кагачева</surname><given-names>Т. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kagacheva</surname><given-names>T. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кагачева Татьяна Игоревна — врач по эндоваскулярным диагностике и лечению</p><p>197758, Санкт-Петербург, п. Песочный, ул. Ленинградская, д. 70</p></bio><bio xml:lang="en"><p>197758, Saint Petersburg, p. Pesochny, Leningradskaya str., 70</p></bio><email xlink:type="simple">tatiana.kagacheva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7683-5042</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Поликарпов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Polikarpov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Поликарпов Алексей Александрович — главный научный сотрудник отдела интервенционной радиологии и оперативной хирургии, д.м.н., профессор кафедры радиологии,хирургии и онкологии, д.м.н., заслуженный врач России</p><p>SPIN-код 4641-0720</p><p>197758, Санкт-Петербург, п. Песочный, ул. Ленинградская, д. 70</p></bio><bio xml:lang="en"><p>197758, Saint Petersburg, p. Pesochny, Leningradskaya str., 70</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1011-4533</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моисеенко</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Moiseenko</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Моисеенко Андрей Викторович — врач по эндоваскулярным диагностике и лечению</p><p>197758, Санкт-Петербург, п. Песочный, ул. Ленинградская, д. 70</p></bio><bio xml:lang="en"><p>197758, Saint Petersburg, p. Pesochny, Leningradskaya str., 70</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российский научный центр радиологии и хирургических технологий им. акад. А.М. Гранова Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.M. Granov Russian Research Center of Radiology and Surgical Technologies</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>16</day><month>03</month><year>2022</year></pub-date><volume>5</volume><issue>1</issue><elocation-id>83–91</elocation-id><permissions><copyright-statement>Copyright &amp;#x00A9; Таразов П.Г., Кагачева Т.И., Поликарпов А.А., Моисеенко А.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Таразов П.Г., Кагачева Т.И., Поликарпов А.А., Моисеенко А.В.</copyright-holder><copyright-holder xml:lang="en">Tarazov P.G., Kagacheva T.I., Polikarpov A.A., Moiseenko A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.oncoradjournal.ru/jour/article/view/223">https://www.oncoradjournal.ru/jour/article/view/223</self-uri><abstract><p>Представлены наблюдения двух больных нерезектабельной формой внутрипеченочной холангиокарциномы с длительным периодом выживаемости, у которых проводили комбинированную системно-регионарную химиотерапию. Использовали внутриартериальные химиоэмболизацию, химиоинфузию и системную терапию по схемам GEMOX, FOLFIRINOX и GEMCIS, которые не прекращали и после внепеченочного прогрессирования в виде появления метастазов в легкие и кости. Непрерывная симптоматическая, нутритивная поддержка как во время лечения, так и на подготовительном этапе позволила минимизировать токсические проявления и максимально сохранить качество жизни пациентов в течение трех лет десяти месяцев в одном случае и четырех лет по настоящее время в другом. Рассматривается значение факторов, способствовавших длительной выживаемости пациентов с распространенной внутрипеченочной холангиокарциномой. </p></abstract><trans-abstract xml:lang="en"><p>We present two patients with advanced unresectable intrahepatic cholangiocarcinoma successfully treated with combined systemic-regional chemotherapy. Intra-arterial treatment included oily chemoembolization and chemoinfusion (GEMOX) with additional systemic chemotherapy (GEMCIS). Chemotherapy did not stop after extrahepatic progression: metastases to the lungs and bones. Continuous symptomatic nutritional support allowed to minimize chemotherapeutic toxicity and to maintain good quality of life. One patient is still alive for more than 4 years, the other died of tumor progression in three years ten months. The importance of factors contributing to the long-term survival of patients with advanced intrahepatic cholangiocarcinoma is considered.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>внутрипеченочная холангиокарцинома</kwd><kwd>регионарная химиотерапия</kwd><kwd>системная химиотерапия</kwd><kwd>артериальная химиоинфузия</kwd><kwd>химиоэмболизация</kwd><kwd>клинический случай</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cholangiocarcinoma</kwd><kwd>regional chemotherapy</kwd><kwd>systemic chemotherapy</kwd><kwd>arterial chemoinfusion</kwd><kwd>chemoembolization</kwd><kwd>clinical case</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Долгушин БИ, Виршке ЭР, Косырев ВЮ и др. Внутриартериальная химиоэмболизация в лечении неоперабельных больных узловой формой холангиокарциномы. Анналы хирургической гепатологии. 2015;20(3):24-30. DOI: 10.16931/1995-5464.2015324-30.</mixed-citation><mixed-citation xml:lang="en">Dolgushin BI, Virshke ER, Kosyrev VY, et al. Intra-arterial chemoembolization in the treatment of inoperable patients with nodular cholangiocarcinoma. Annals of Surgical Hepatology. 2015;20(3):24-30. (In Russian). DOI: 10.16931/1995-5464.2015324-30.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Таразов ПГ, Кагачева ТИ. Рентгеноэндоваскулярные вмешательства в лечении внутрипеченочной холангиокарциномы (обзор литературы). Диагностическая и интервенционная радиология. 2021;15(3):55-66. DOI: 10.25512/DIR.2021.15.3.06.</mixed-citation><mixed-citation xml:lang="en">Tarazov PG, Kagacheva TY. Roentgenoendovascular interventions in the treatment of intrahepatic cholangiocarcinoma (review). Diagnostic and Interventional Radiology. 2021;15(3):55-66. (In Russian. DOI: 10.25512/DIR.2021.15.3.06.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepaticartery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015;111(2):213-20. DOI: 10.1002/jso.23781.</mixed-citation><mixed-citation xml:lang="en">Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepaticartery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015;111(2):213-20. DOI: 10.1002/jso.23781.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Buettner S, Braat AJAT, Margonis GA, et al. Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: A multicenter retrospective analysis. J Vasc Interv Radiol. 2020;31(7):1035-43. E2. DOI: 10.1016/j.jvir.2020.02.008.</mixed-citation><mixed-citation xml:lang="en">Buettner S, Braat AJAT, Margonis GA, et al. Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: A multicenter retrospective analysis. J Vasc Interv Radiol. 2020;31(7):1035-43. E2. DOI: 10.1016/j.jvir.2020.02.008.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol. 2020;6(1):51-9. DOI: 10.1001/jamaoncol.2019.3702.</mixed-citation><mixed-citation xml:lang="en">Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol. 2020;6(1):51-9. DOI: 10.1001/jamaoncol.2019.3702.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Konstantinidis IT, Koerkamp BG, Do RKG, et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016;122(5):758-65. DOI: 10.1002/cncr.29824.</mixed-citation><mixed-citation xml:lang="en">Konstantinidis IT, Koerkamp BG, Do RKG, et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016;122(5):758-65. DOI: 10.1002/cncr.29824.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mosconi C, Solaini L, Vara G, et al. Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma — a systemic review and meta-analysis. Cardiovasc. Intervent Radiol. 2021;44(5):728-38. DOI: 10.1007/s00270-021-02800-w</mixed-citation><mixed-citation xml:lang="en">Mosconi C, Solaini L, Vara G, et al. Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma  — a systemic review and meta-analysis. Cardiovasc. Intervent Radiol. 2021;44(5):728-38. DOI: 10.1007/s00270-021-02800-w</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Yu Q, Liu C, Pillai A, Ahmed O. Twenty years of radiation therapy of unresectable intrahepatic cholangiocarcinoma: Internal or external? A systematic review and meta-analysis. Liver Cancer. 2021;10(5):433-50. DOI: 10.1159/000516880.</mixed-citation><mixed-citation xml:lang="en">Yu Q, Liu C, Pillai A, Ahmed O. Twenty years of radiation therapy of unresectable intrahepatic cholangiocarcinoma: Internal or external? A systematic review and meta-analysis. Liver Cancer. 2021;10(5):433-50. DOI: 10.1159/000516880.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Шипилова АН. Лекарственное лечение билиарного рака. В кн.: Холангиоцеллюлярная карцинома. Чжао АВ, ред. ГЭОТАР-Медиа, 2021, С. 277-338. DOI: 10.33029/9704-5955-3-CC-2021-1-368.</mixed-citation><mixed-citation xml:lang="en">Shipilova AN. Medical treatment of biliary cancer. In: Cholangiocellular carcinoma. Zhao AV, ed. GEOTAR-Media, 2021. P. 277-338 (In Russian). DOI: 10.33029/9704-5955-3-CC-2021-1-368.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Nooijen LE, Franken LC, Belkouz A, et al. Efficacy and safety of gemcitabine plus cisplatin as potential preoperative chemotherapy in locally advanced intrahepatic, perihilar, and mid-cholangiocarcinoma: A retrospective cohort study. Am J Clin Oncol. 2021;44(10):526-32. DOI: 10.1097/COC.0000000000000861.</mixed-citation><mixed-citation xml:lang="en">Nooijen LE, Franken LC, Belkouz A, et al. Efficacy and safety of gemcitabine plus cisplatin as potential preoperative chemotherapy in locally advanced intrahepatic, perihilar, and mid-cholangiocarcinoma: A retrospective cohort study. Am J Clin Oncol. 2021;44(10):526-32. DOI: 10.1097/COC.0000000000000861.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ogasawara S, Ooka Y, Koroki K, et al. Switching to systemic therapy after locoregional treatment failure: Definition and best timing (review). Clin Mol Hepatol. 2020;26(2):155-62. DOI: 10.3350/cmb.2019.0021n.</mixed-citation><mixed-citation xml:lang="en">Ogasawara S, Ooka Y, Koroki K, et al. Switching to systemic therapy after locoregional treatment failure: Definition and best timing (review). Clin Mol Hepatol. 2020;26(2):155-62. DOI: 10.3350/cmb.2019.0021n.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers. 2021;13(3):558. DOI: 10.3390/cancers13030558.</mixed-citation><mixed-citation xml:lang="en">Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers. 2021;13(3):558. DOI: 10.3390/cancers13030558.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Бредер ВВ, Базин ИС, Косырев ВЮ, Ледин ЕВ. Практические рекомендации по лекарственному лечению билиарного рака. Злокачественные опухоли: Практические рекомендации RUSSCO#3s2, 2021:11(26):452-67. DOI: 10.18027/2224-50-57-2021-11-3s2-26.</mixed-citation><mixed-citation xml:lang="en">Breder VV, Bazin IS, Kosyrev VY, Ledin E.V. Practical recommendations on medical treatment of biliary cancer. Malignant tumors: Practical recommendations RUSSCO #3s2, 2021:11(26):452-67 (In Russian). DOI: 10.18027/2224-50-57-2021-11-3s2-26.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
